• WHO granted prequalification to the novel oral polio vaccine type 2 (nOPV2) after receiving the full license.

• nOPV2, which was initially granted Emergency Use Listing in response to poliovirus type 2 outbreaks, has safeguarded millions against polio.

• Over a billion doses of nOPV2 have been administered since Emergency Use Listing approval, with surveillance data confirming its efficacy.

• nOPV2 development, based on decades of oral polio vaccine research, proposed genetic stability modifications in 2011.

• PATH has played a key role as the facilitator of the nOPV2 product development consortium, facilitating data-sharing and technical assistance.

• A Phase 3 study sponsored by PATH and Bio Farma, the manufacturer, whose efforts enabled rapid supply under Emergency Use Listing contributed to WHO's prequalification decision.

• Ongoing work by PATH and Bio Farma includes developing nOPVs against polio types 1 and 3.

• PATH focuses on non-infectious polio vaccines, treatment for poliovirus shedding, diagnostics, surveillance, and international standards.

Click here to read more